Why Did Sun Pharmaceutical Industries Limited (SUNPHARMA) Share Price Fall 2.71% Today?
Price Performance Summary
Key Reasons for Today's Fall
Sun Pharmaceutical Industries Limited (SUNPHARMA) shares fell 2.71% on 22 May 2026, closing at ₹1840.00. Today's news shows: Sun Pharma Q4: Revenue at 146B Rupees, US Sales Slip 1.1% to $459 Million - scanx.trade. Volume today was 36.1L shares, 1.0x the 30-day average — reflecting moderate participation. Sector performance data unavailable, with the stock outperforming its sector. Investors should monitor follow-up volume and any further news in coming sessions to confirm the trend.
Sector & Market Context
Sun Pharmaceutical Industries Limited operates in the Pharmaceuticals sector. Tracking sector peers and the broader index helps determine whether the move is company-specific or part of a wider trend.
Latest News on Sun Pharmaceutical Industries Limited
Showing news from last 48 hours
Sun Pharma Q4: Revenue at 146B Rupees, US Sales Slip 1.1% to $459 Million - scanx.trade
Sun Pharma Q4: Revenue at 146B Rupees, US Sales Slip 1.1% to $459 Million scanx.trade
Sun Pharma Q4 results 2026: Profit jumps 26% YoY to ₹2,714 crore; recommends final dividend of ₹5 for FY26
Sun Pharma Q4 results 2026: Profit jumped 26% YoY to ₹2,714 crore. Total revenue from operations for the quarter under review rose 12.8% YoY to ₹14,611.79 crore. Sun Pharma's board recommended a fin...
Frequently Asked Questions About Sun Pharmaceutical Industries Limited
Why did Sun Pharmaceutical Industries Limited share price fall today?
Sun Pharmaceutical Industries Limited (SUNPHARMA) fell 2.71% on 22 May 2026 due to Sun Pharma Q4: Revenue at 146B Rupees, US Sales Slip 1.1% to $459 Million - scanx.trade. Trading volume was 36.1L shares.
What is Sun Pharmaceutical Industries Limited's 52-week high and low?
52-week high/low data is not available for Sun Pharmaceutical Industries Limited at this time.
Is Sun Pharmaceutical Industries Limited a good stock to watch after today's move?
Today's 2.7% fall in SUNPHARMA on 36.1L volume is worth tracking. Investors should monitor follow-through price action and upcoming corporate announcements. This is not financial advice — please consult a SEBI-registered advisor before investing.
Disclaimer: NiftyPulse360 is not a SEBI-registered investment advisor. The information above is for educational purposes only and should not be construed as financial advice. Always consult a qualified advisor before making investment decisions.
💼 Expert View
Analyst ratings and broker views for Sun Pharmaceutical Industries Limitedare tracked across major brokerages including Motilal Oswal, ICICI Securities, and HDFC Securities. Investors should consider the consensus target price, upcoming earnings calendar, and any analyst upgrade/downgrade actions when evaluating today's decline. Compare with sector peers GLENMARK, AUROPHARMA, ZYDUSLIFE for relative strength analysis.
Note: NiftyPulse360 does not provide buy/sell recommendations. Consult a SEBI-registered investment advisor before making decisions.